# BCL11A

## Overview
BCL11A is a gene that encodes the BCL11 transcription factor A, a zinc finger transcription factor involved in various biological processes, including the regulation of hemoglobin switching and neurodevelopment. The BCL11A protein is characterized by its zinc finger domains, which facilitate its role as a transcriptional repressor by binding to specific DNA sequences. This protein is crucial in the silencing of fetal hemoglobin (HbF) expression in adult erythroid cells, a process essential for normal erythropoiesis. BCL11A interacts with several corepressor complexes, such as the nucleosome remodeling and deacetylase (NuRD) complex, to maintain HbF silencing and promote chromosomal interactions within the β-globin locus. Beyond its role in hemoglobin regulation, BCL11A is implicated in various diseases, including hematological malignancies and certain cancers, where it often acts as a proto-oncogene. Its expression levels and interactions are critical in these contexts, making it a potential target for therapeutic interventions (Liu2018Direct; Basak2015BCL11A; Xu2013Corepressordependent).

## Structure
The BCL11A protein is a transcription factor characterized by its zinc finger domains, which are crucial for its DNA-binding capability. It contains a triple zinc finger domain, ZnF456, responsible for interacting with specific DNA sequences. The zinc fingers are modular structures composed of an antiparallel β-sheet and an α-helix, held together by a zinc ion and hydrophobic residues. ZnF4 and ZnF5 bind to the major groove of DNA, while ZnF6 engages the minor groove, contributing to the binding affinity through entropic contributions (Viennet2024Structural).

The primary structure of BCL11A includes specific motifs such as FSXXLXXL and VYSXWLXXY, which are essential for interactions with nuclear receptors like COUP-TFII (Chan2013A). The secondary structure involves canonical C2H2 zinc finger folds, consisting of two β-strands and one C-terminal α-helix (Yang2019Structural). BCL11A undergoes alternative splicing, producing multiple isoforms, including BCL11A-XL, which is a DNA-sequence-specific transcriptional repressor (Liu2006Functional). The protein also undergoes post-translational modifications, such as phosphorylation, which may influence its function.

## Function
BCL11A is a zinc-finger transcription factor that plays a critical role in the regulation of hemoglobin switching, particularly in the silencing of fetal hemoglobin (HbF) expression in adult erythroid cells. It functions as a transcriptional repressor by binding to specific DNA motifs, such as the TGACCA motif, within the gamma-globin promoters, thereby silencing their expression (Liu2018Direct). This repression is crucial for the transition from fetal to adult hemoglobin, a process that is significant for normal erythropoiesis and red blood cell development (Xu2013Corepressordependent).

BCL11A interacts with several corepressor complexes, including the nucleosome remodeling and deacetylase (NuRD) complex, to maintain HbF silencing. It is involved in promoting long-range chromosomal interactions within the β-globin locus, which is essential for the developmental switch from fetal to adult hemoglobin (Xu2013Corepressordependent). The presence of BCL11A at the gamma-globin promoter is suggested to be incompatible with stable loop formation, which is necessary for the expression of gamma-globin genes (Liu2018Direct).

Beyond its role in hemoglobin regulation, BCL11A is also implicated in neurodevelopmental processes and is expressed in developing red blood cell precursors and the brain (Basak2015BCL11A).

## Clinical Significance
The BCL11A gene is implicated in various diseases due to mutations, altered expression levels, or disruptions in its normal interactions. In hematological malignancies, BCL11A acts as a proto-oncogene. It is overexpressed in B-cell chronic lymphocytic leukemia and is involved in chromosomal translocations, such as t(2;14)(p13;q32.3), which are associated with aggressive forms of the disease (Liu2006Functional; Satterwhite2001The). BCL11A is also overexpressed in non-small cell lung cancer (NSCLC), where it is associated with lymph node status and patient survival, suggesting a role in tumor progression (Jiang2013BCL11A).

In breast cancer, particularly triple-negative breast cancer (TNBC), BCL11A is overexpressed and promotes tumor formation. Its knockdown in TNBC cell lines suppresses tumorigenic potential, indicating its role as an oncogene in this context (Kątnik2023BCL11A). In natural killer/T-cell lymphoma (NKTL), BCL11A is upregulated and associated with poor clinical outcomes, suggesting its potential as a prognostic biomarker (Shi2020BCL11A).

BCL11A also plays a critical role in the regulation of fetal hemoglobin (HbF) expression. Alterations in BCL11A expression can lead to increased HbF levels, which are beneficial in conditions like sickle cell disease and beta-thalassemia, as they ameliorate disease severity (Liu2018Direct; Sankaran2008Human).

## Interactions
BCL11A is a zinc finger transcription factor that participates in various interactions with proteins and nucleic acids, playing a crucial role in gene regulation. It directly binds to the γ-globin gene promoter, specifically the γ-globin -115 HPFH region, through its C-terminal zinc fingers (Znf4-6), with Znf4 and Znf5 making significant contacts with the DNA sequence TTGACCA (Yang2019Structural). BCL11A also interacts with the NuRD chromatin remodeling complex, which is essential for its repressive function on globin genes (Liu2018Direct).

In erythroid cells, BCL11A forms a multiprotein complex with SOX6 and GATA1, which is crucial for the silencing of γ-globin transcription. This complex is involved in chromosomal looping and long-range interactions within the β-globin locus (Xu2010Transcriptional). BCL11A also interacts with the Mi-2/NuRD complex components, such as MBD3, HDAC1, and HDAC2, indicating its role in transcriptional repression (Xu2010Transcriptional).

In B-cell lines, BCL11A-XL, a splice variant, interacts with BCL6 and is localized in nuclear paraspeckles, suggesting a role in transcriptional regulation within these subnuclear domains (Liu2006Functional). BCL11A isoforms can form homomeric and heteromeric complexes, influencing their DNA binding and transcriptional regulatory properties (Liu2006Functional).


## References


[1. (Xu2013Corepressordependent) Jian Xu, Daniel E. Bauer, Marc A. Kerenyi, Thuy D. Vo, Serena Hou, Yu-Jung Hsu, Huilan Yao, Jennifer J. Trowbridge, Gail Mandel, and Stuart H. Orkin. Corepressor-dependent silencing of fetal hemoglobin expression by bcl11a. Proceedings of the National Academy of Sciences, 110(16):6518–6523, April 2013. URL: http://dx.doi.org/10.1073/pnas.1303976110, doi:10.1073/pnas.1303976110. This article has 177 citations.](https://doi.org/10.1073/pnas.1303976110)

2. (Viennet2024Structural) Structural Insights into the DNA-Binding Mechanism of BCL11A: The Integral Role of ZnF6. This article has 0 citations.

[3. (Xu2010Transcriptional) Jian Xu, Vijay G. Sankaran, Min Ni, Tobias F. Menne, Rishi V. Puram, Woojin Kim, and Stuart H. Orkin. Transcriptional silencing of γ-globin by bcl11a involves long-range interactions and cooperation with sox6. Genes &amp; Development, 24(8):783–798, April 2010. URL: http://dx.doi.org/10.1101/gad.1897310, doi:10.1101/gad.1897310. This article has 290 citations.](https://doi.org/10.1101/gad.1897310)

[4. (Liu2006Functional) Hui Liu, Gregory C Ippolito, Jason K Wall, Teresa Niu, Loren Probst, Baeck-Seung Lee, Karen Pulford, Alison H Banham, Luke Stockwin, Arthur L Shaffer, Louis M Staudt, Chhaya Das, Martin JS Dyer, and Philip W Tucker. Functional studies of bcl11a: characterization of the conserved bcl11a-xl splice variant and its interaction with bcl6 in nuclear paraspeckles of germinal center b cells. Molecular Cancer, May 2006. URL: http://dx.doi.org/10.1186/1476-4598-5-18, doi:10.1186/1476-4598-5-18. This article has 66 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/1476-4598-5-18)

[5. (Jiang2013BCL11A) Ben-yuan Jiang, Xu-chao Zhang, Jian Su, Wei Meng, Xue-ning Yang, Jin-ji Yang, Qing Zhou, Zhi-yong Chen, Zhi-hong Chen, Zhi Xie, Shi-liang Chen, and Yi-long Wu. Bcl11a overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microrna-30a and gene amplification. Molecular Cancer, June 2013. URL: http://dx.doi.org/10.1186/1476-4598-12-61, doi:10.1186/1476-4598-12-61. This article has 39 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/1476-4598-12-61)

[6. (Shi2020BCL11A) Hongyun Shi, Chun Li, Wei Feng, Jianjun Yue, Jingfang Song, Aizhi Peng, and Hua Wang. Bcl11a is oncogenic and predicts poor outcomes in natural killer/t-cell lymphoma. Frontiers in Pharmacology, June 2020. URL: http://dx.doi.org/10.3389/fphar.2020.00820, doi:10.3389/fphar.2020.00820. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2020.00820)

[7. (Liu2018Direct) Nan Liu, Victoria V. Hargreaves, Qian Zhu, Jesse V. Kurland, Jiyoung Hong, Woojin Kim, Falak Sher, Claudio Macias-Trevino, Julia M. Rogers, Ryo Kurita, Yukio Nakamura, Guo-Cheng Yuan, Daniel E. Bauer, Jian Xu, Martha L. Bulyk, and Stuart H. Orkin. Direct promoter repression by bcl11a controls the fetal to adult hemoglobin switch. Cell, 173(2):430-442.e17, April 2018. URL: http://dx.doi.org/10.1016/j.cell.2018.03.016, doi:10.1016/j.cell.2018.03.016. This article has 399 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2018.03.016)

[8. (Sankaran2008Human) Vijay G. Sankaran, Tobias F. Menne, Jian Xu, Thomas E. Akie, Guillaume Lettre, Ben Van Handel, Hanna K. A. Mikkola, Joel N. Hirschhorn, Alan B. Cantor, and Stuart H. Orkin. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor bcl11a. Science, 322(5909):1839–1842, December 2008. URL: http://dx.doi.org/10.1126/science.1165409, doi:10.1126/science.1165409. This article has 713 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.1165409)

[9. (Chan2013A) Chun Ming Chan, Joel Fulton, Cristina Montiel-Duarte, Hilary M. Collins, Neetu Bharti, Frances R. Wadelin, Paula M. Moran, Nigel P. Mongan, and David M. Heery. A signature motif mediating selective interactions of bcl11a with the nr2e/f subfamily of orphan nuclear receptors. Nucleic Acids Research, 41(21):9663–9679, August 2013. URL: http://dx.doi.org/10.1093/nar/gkt761, doi:10.1093/nar/gkt761. This article has 17 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkt761)

[10. (Kątnik2023BCL11A) Ewa Kątnik, Agnieszka Gomułkiewicz, Aleksandra Piotrowska, Jędrzej Grzegrzółka, Agnieszka Rusak, Alicja Kmiecik, Katarzyna Ratajczak-Wielgomas, and Piotr Dzięgiel. Bcl11a expression in breast cancer. Current Issues in Molecular Biology, 45(4):2681–2698, March 2023. URL: http://dx.doi.org/10.3390/cimb45040175, doi:10.3390/cimb45040175. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cimb45040175)

[11. (Satterwhite2001The) Ed Satterwhite, Takashi Sonoki, Tony G. Willis, Lana Harder, Rachael Nowak, Emma L. Arriola, Hui Liu, Helen P. Price, Stefan Gesk, Doris Steinemann, Brigitte Schlegelberger, David G. Oscier, Reiner Siebert, Philip W. Tucker, and Martin J. S. Dyer. The bcl11 gene family: involvement of bcl11a in lymphoid malignancies. Blood, 98(12):3413–3420, December 2001. URL: http://dx.doi.org/10.1182/blood.v98.12.3413, doi:10.1182/blood.v98.12.3413. This article has 242 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood.v98.12.3413)

[12. (Yang2019Structural) Yang Yang, Ziyan Xu, Chao He, Beibei Zhang, Yunyu Shi, and Fudong Li. Structural insights into the recognition of γ-globin gene promoter by bcl11a. Cell Research, 29(11):960–963, August 2019. URL: http://dx.doi.org/10.1038/s41422-019-0221-0, doi:10.1038/s41422-019-0221-0. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41422-019-0221-0)

[13. (Basak2015BCL11A) Anindita Basak, Miroslava Hancarova, Jacob C. Ulirsch, Tugce B. Balci, Marie Trkova, Michal Pelisek, Marketa Vlckova, Katerina Muzikova, Jaroslav Cermak, Jan Trka, David A. Dyment, Stuart H. Orkin, Mark J. Daly, Zdenek Sedlacek, and Vijay G. Sankaran. Bcl11a deletions result in fetal hemoglobin persistence and neurodevelopmental alterations. Journal of Clinical Investigation, 125(6):2363–2368, May 2015. URL: http://dx.doi.org/10.1172/jci81163, doi:10.1172/jci81163. This article has 121 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci81163)